Now showing items 1-6 of 6
Predicting the Risk of Huntington's Disease with Multiple Longitudinal Biomarkers.
(Journal of Huntington's disease, 2019-06-22)
BACKGROUND:Huntington's disease (HD) has gradually become a public health threat, and there is a growing interest in developing prognostic models to predict the time for HD diagnosis. OBJECTIVE:This study aims to develop ...
A prognostic model of Alzheimer's disease relying on multiple longitudinal measures and time-to-event data.
(Alzheimer's & dementia : the journal of the Alzheimer's Association, 2018-05)
INTRODUCTION:Characterizing progression in Alzheimer's disease is critically important for early detection and targeted treatment. The objective was to develop a prognostic model, based on multivariate longitudinal markers, ...
Bayesian Functional Joint Models for Multivariate Longitudinal and Time-to-Event Data.
(Computational statistics & data analysis, 2019-01)
A multivariate functional joint model framework is proposed which enables the repeatedly measured functional outcomes, scalar outcomes, and survival process to be modeled simultaneously while accounting for association among ...
A Bayesian approach for individual-level drug benefit-risk assessment.
(Statistics in medicine, 2019-07)
In existing benefit-risk assessment (BRA) methods, benefit and risk criteria are usually identified and defined separately based on aggregated clinical data and therefore ignore the individual-level differences as well as ...
Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database.
(Annals of surgical oncology, 2019-06-17)
BACKGROUND:Although the National Comprehensive Cancer Network (NCCN) guidelines recommend use of lymph node dissection (LND) in patients with pancreatic neuroendocrine tumors (pNETs) > 2 cm, there is limited evidence to ...
Periodic benefit-risk assessment using Bayesian stochastic multi-criteria acceptability analysis.
(Contemporary clinical trials, 2018-04)
Benefit-risk (BR) assessment is essential to ensure the best decisions are made for a medical product in the clinical development process, regulatory marketing authorization, post-market surveillance, and coverage ...